This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), is focused on developing a novel, non-hormonal therapeutic for endometriosis. The $2,045,782 award to Endomet Biosciences, Inc., a woman-owned small business, will support activities necessary to commence Phase 1 clinical trials for their ENDO-205 compound. Key objectives include manufacturing GMP clinical drug...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Opal Therapeutics Inc. aims to develop an advanced screening platform that utilizes patient-derived uterine organoids to identify new therapeutic Proteolysis-Targeting Chimeras (PROTACs) for treating uterine fibroids and endometriosis. The project goals include building a comprehensive gynecological biobank, training AI algorithms to detect disease-relevant phenotypes,...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $474,946 to develop a novel, non-hormonal, female-initiated contraceptive device. The research aims to create a dual-compartment vaginal device that enables women to self-administer a bioresponsive polymer fiber mat and a supplemental fluid to fortify natural contraceptive barriers at the...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,154,752 to Endeavor Health Clinical Operations, a non-profit healthcare and research institution, over the period of September 17, 2024 to August 31, 2027. The grant will fund a randomized controlled trial (N=300) to investigate how individual variability in...
This R01 grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $1,924,239 to Baylor College of Medicine to perform preclinical drug development studies to create potent, selective, metabolically stable, and peripherally restricted serine/threonine kinase 33 (STK33) inhibitors as first-in-class non-hormonal contraceptive drugs for men. The specific aims are to: 1) use...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $298,883 to Iaterion, Inc. to develop a safer menopausal hormone therapy (MHT) formula that can be used long-term to treat protracted menopausal symptoms and prevent chronic diseases like osteoporosis, diabetes, obesity, and metabolic syndrome. The project aims to create an estradiol/reprogramming ligand combination that can potentially replace the progestin component of current MHT...
The National Institute on Aging (NIA) awarded a $391,101 Project Grant under the Aging Research program (CFDA 93.866) to The Ohio State University to develop a novel nonsteroidal and nonhormonal agent that reverses menopause-related loss of genital epithelial integrity and function. The research aims to define the mechanism of action, optimize delivery, and establish the long-term safety profile of an EFNA3-mimetic agonist peptide (EFNA3-MAP) administered intravaginally to restore genital...
This Project Grant award, totaling $1,624,100.00, was provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant aims to understand the role of the tumor suppressors REST and MED12 in regulating estrogen-progesterone pathways in uterine fibroids, which are the most common clinical indication for hysterectomy. The research will utilize genetically modified mouse models to...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $328,496 to Pelva Health Corporation to develop a novel hydrogel film and applicator delivery system to reduce pain experienced during sexual intercourse for women with vulvodynia. The goal is to create a non-pharmaceutical solution that can help mitigate pain receptor activity and allow for...
This Project Grant award from the National Institute of Child Health and Human Development, under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop a transdermal patch for the treatment of pregnancy-induced nausea and vomiting (PINV). The $333,284 award to Integurx Therapeutics LLC will fund efforts to optimize the product design, produce pilot-scale patches, and conduct safety studies for a novel transdermal delivery system of the anti-nausea drug...